Drug Criteria & Outcomes: In the Pipeline
Drug Criteria & Outcomes: In the Pipeline
• Antigenics has announced that investigators have enrolled the first patient in a Phase III trial of its personalized cancer vaccine HSPPC-96 (Oncophage) for the treatment of metastatic melanoma.
• Boston Scientific Corporation has announced that the Food and Drug Administration (FDA) has authorized full enrollment of its TAXUS IV clinical trial. The prospective, randomized, double-blind trial is designed to assess the safety and efficacy of a slow-release dose formulation, paclitaxel-eluting TAXUS stent system for the treatment of coronary restenosis.
• Inspire Pharmaceuticals has announced the launch of two Phase IIa studies for INS37217 intranasal solution in a nasal spray formulation. Both studies are double-blind, placebo-controlled, dose-ranging studies. One is being conducted in 60 patients with chronic rhinitis. The other is being conducted in 90 patients with upper respiratory infections.
• Protein Design Labs has initiated a Phase II clinical trial to evaluate its humanized SMART Anti-Gamma Interferon Antibody in Crohn’s disease.
• Paris-Immuno-Designed Molecules, S.A. (IDM), and its U.S. subsidiary, IDM, have announced approval from the FDA to begin a Phase III clinical trial in the treatment of ovarian cancer using IDM’s Cell Drug Osidem (also known as IDM-1).
• Cell Therapeutics has announced that it is continuing a Phase II clinical trial of polyglutamate paclitaxel (Xyotax) in non-small cell lung cancer.
• Human Genome Sciences has announced that the FDA has cleared the company’s Investigational New Drug application to begin clinical trials of LymphoRad(131) (LymphoRad). The initial Phase I clinical trial will evaluate LymphoRad in patients with multiple myeloma.
• Oncolytics Biotech has received approval from Health Canada to initiate a Phase I/II clinical trial to investigate the use of the human reovirus (Reolysin) as a treatment for patients with recurrent malignant glioma.
• Avanir Pharmaceuticals has completed enrollment in a Phase II/III clinical trial of Neurodex in the treatment of emotional lability. Neurodex is a patented, orally administered combination of dextromethorphan (DM) and an enzyme inhibitor that sustains elevated levels of DM in the human body and allows for a 12-hour dosing schedule.
• Amylin Pharmaceuticals has initiated a dose titration study of pramlintide acetate (Symlin) in patients with Type 1 diabetes who are actively trying to improve their glucose control.
• Telikhas initiated a Phase I-IIa clinical trial of the TLK199 small molecule product candidate in patients with myelodysplastic syndrome.
• DynPort Vaccine Co., a joint venture between DynCorp of Reston, Va., and Porton International, announced that it would enter into a Phase I clinical trial for a new smallpox vaccine.
* Pharmacyclics is planning to conduct an additional Phase III clinical trial of its lead product motexafin gadolinium (Xcytrin) Injection. Last year, the company reported results of a randomized controlled Phase III trial of motexafin gadolinium in patients with brain metastases.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.